SBI Securities Co. Ltd. Invests $277,000 in Novavax, Inc. (NASDAQ:NVAX)

SBI Securities Co. Ltd. bought a new position in Novavax, Inc. (NASDAQ:NVAX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 34,485 shares of the biopharmaceutical company's stock, valued at approximately $277,000.

Other large investors have also added to or reduced their stakes in the company. Spire Wealth Management bought a new stake in shares of Novavax during the 4th quarter valued at about $29,000. KBC Group NV boosted its position in shares of Novavax by 97.0% during the 4th quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock valued at $64,000 after acquiring an additional 3,917 shares during the last quarter. TigerOak Management L.L.C. bought a new stake in shares of Novavax during the 4th quarter valued at about $86,000. US Bancorp DE raised its holdings in shares of Novavax by 3,538.8% during the 3rd quarter. US Bancorp DE now owns 12,299 shares of the biopharmaceutical company's stock valued at $155,000 after buying an additional 11,961 shares in the last quarter. Finally, Entropy Technologies LP purchased a new position in shares of Novavax during the 3rd quarter valued at about $158,000. Institutional investors own 53.04% of the company's stock.

Novavax Price Performance

Novavax stock traded up $0.47 during trading hours on Friday, reaching $8.34. The company had a trading volume of 5,070,652 shares, compared to its average volume of 8,084,745. The company has a 50-day moving average price of $8.46 and a 200 day moving average price of $9.79. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -3.69, a P/E/G ratio of 2.85 and a beta of 2.92. Novavax, Inc. has a 12-month low of $3.81 and a 12-month high of $23.86.

Remove Ads

Novavax (NASDAQ:NVAX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.24. The company had revenue of $88.31 million during the quarter, compared to analysts' expectations of $85.48 million. During the same period last year, the firm earned ($1.44) earnings per share. As a group, research analysts expect that Novavax, Inc. will post -1.46 earnings per share for the current year.

Insider Activity

In other news, Director Rachel K. King sold 4,150 shares of the business's stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $9.02, for a total transaction of $37,433.00. Following the transaction, the director now directly owns 14,770 shares of the company's stock, valued at approximately $133,225.40. The trade was a 21.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James F. Young sold 5,400 shares of the business's stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total value of $43,200.00. Following the transaction, the director now directly owns 51,760 shares in the company, valued at $414,080. This trade represents a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 14,150 shares of company stock valued at $119,641. Company insiders own 1.00% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. TD Cowen raised Novavax to a "hold" rating in a report on Thursday, February 27th. HC Wainwright reissued a "buy" rating and set a $19.00 price objective on shares of Novavax in a report on Tuesday, December 10th. Finally, BTIG Research assumed coverage on Novavax in a report on Friday, February 28th. They set a "buy" rating and a $19.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $18.00.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.